Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice

Simple item page
dc.contributor.authorMahony, D.
dc.contributor.authorCavallaro, A.
dc.contributor.authorStahr, F.
dc.contributor.authorMahony, T.
dc.contributor.authorQiao, S.
dc.contributor.authorMitter, N.
dc.date.issued2013
dc.description.abstractImmunization to the model protein antigen ovalbumin (OVA) is investigated using MCM-41 mesoporous silica nanoparticles as a novel vaccine delivery vehicle and adjuvant system in mice. The effects of amino surface functionalization and adsorption time on OVA adsorption to nanoparticles are assessed. Amino-functionalized MCM-41 (AM-41) shows an effect on the amount of OVA binding, with 2.5-fold increase in binding capacity (72 mg OVA/g AM-41) compared to nonfunctionalized MCM-41 (29 mg OVA/g MCM-41). Immunization studies in mice with a 10 μg dose of OVA adsorbed to AM-41 elicits both antibody and cell-mediated immune responses following three subcutaneous injections. Immunizations at a lower 2 μg dose of OVA adsorbed to AM-41 particles results in an antibody response but not cell-mediated immunity. The level of antibody responses following immunization with nanoformulations containing either 2 μg or 10 μg of OVA are only slightly lower than that in mice which receive 50 μg OVA adjuvanted with QuilA, a crude mixture of saponins extracted from the bark of the Quillaja saponaria Molina tree. This is a significant result, since it demonstrates that AM-41 nanoparticles are self-adjuvanting and elicit immune responses at reduced antigen doses in vivo compared to a conventional delivery system. Importantly, there are no local or systemic negative effects in animals injected with AM-41. Histopathological studies of a range of tissue organs show no changes in histopathology of the animals receiving nanoparticles over a six week period. These results establish the biocompatible MCM-41 silica nanoparticles as a new method for vaccine delivery which incorporates a self-adjuvant effect.
dc.description.statementofresponsibilityDonna Mahony, Antonino S. Cavallaro, Frances Stahr, Timothy J. Mahony, Shi Zhang Qiao, Neena Mitter
dc.identifier.citationSmall, 2013; 9(18):3138-3146
dc.identifier.doi10.1002/smll.201300012
dc.identifier.issn1613-6810
dc.identifier.issn1613-6829
dc.identifier.orcidQiao, S. [0000-0002-1220-1761] [0000-0002-4568-8422]
dc.identifier.urihttp://hdl.handle.net/2440/80690
dc.language.isoen
dc.publisherWiley - VCH Verlag GmbH & Co KGaA
dc.rightsCopyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
dc.source.urihttps://doi.org/10.1002/smll.201300012
dc.subjectadjuvants
dc.subjectmesoporous silica nanoparticles
dc.subjectvaccines
dc.subjectdrug delivery
dc.titleMesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Chemical Engineering publications